TRAVERE THERAPEUTICS, INC.
Income Statement
| Line Item | Jul 2026 | Jun 2026 | Apr 2026 | Mar 2026 | Feb 2026 | Dec 2025 | Oct 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $169.6M | — | $127.2M | — | — | — | $164.9M |
| Cost of Revenue | — | $2.2M | — | $2.0M | — | — | — | $1.6M |
| Gross Profit | — | $167.4M | — | $125.2M | — | — | — | $163.3M |
| Gross Margin | — | 98.7% | — | 98.5% | — | — | — | 99.0% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $96.1M | — | $80.3M | — | — | — | $86.5M |
| Operating Income | — | $4.0M | — | $-36.9M | — | — | — | $24.9M |
| Operating Margin | — | 2.3% | — | -29.0% | — | — | — | 15.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-35.0M | — | $-36.7M | — | — | — | $25.7M |
| Income Tax Expense | — | $-204.0K | — | $-120.0K | — | — | — | $8.0K |
| Net Income | — | $-34.8M | — | $-37.1M | — | — | — | $25.7M |
| Net Margin | — | -20.5% | — | -29.2% | — | — | — | 15.6% |
| EPS (Basic) | — | $-0.37 | — | $-0.40 | — | — | — | $0.29 |
| EPS (Diluted) | — | $-0.37 | — | $-0.40 | — | — | — | $0.28 |
| Shares Outstanding (Basic) | 94.3M | 93.5M | 93.0M | 91.9M | 92.2M | 90.9M | 89.5M | 89.2M |
| Shares Outstanding (Diluted) | 94.3M | 93.5M | 93.0M | 91.9M | 92.2M | 90.9M | 89.5M | 102.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |